Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
James Harber
Observed names:
Harber, James,
J. Harber
Institutions:
The University of Western Australia,
Harry Perkins Institute of Medical Research
Observed institutions:
University of Leicester,
The University of Western Australia,
Harry Perkins Institute of Medical Research,
University Hospitals of Leicester NHS Trust
ORCID:
0000-0001-6451-9598
Observed ORCID:
0000-0001-6451-9598
OpenAlex ID:
A5025142126
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
2021
·
Min Zhang
, Jin-Li Luo
, et al.
·
Nature Communications
·
132
PDF
Immunotherapy approaches for malignant pleural mesothelioma
2022
·
Dean A. Fennell
, Sean Dulloo
, et al.
·
Nature Reviews Clinical Oncology
·
65
Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
2021
·
James Harber
, Tamihiro Kamata
, et al.
·
Journal for ImmunoTherapy of Cancer
·
51
PDF
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma
2024
·
Min Zhang
, Aleksandra Bzura
, et al.
·
Nature Communications
·
38
PDF
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial
2025
·
Dean A. Fennell
, Kayleigh Hill
, et al.
·
Nature Communications
·
12
PDF
Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
2021
·
Min Zhang
, Jin-Li Luo
, et al.
·
Nature Communications
·
12
PDF
P2.06-02 Mesothelioma Stratified Therapy (MiST): A Phase IIA Umbrella Trial for Accelerating the Development of Precision Medicines
2019
·
D. Fennell
, M. Hudka
, et al.
·
Journal of Thoracic Oncology
·
6
Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.
2023
·
Dean Anthony Fennell
, Sean Ewings
, et al.
·
Journal of Clinical Oncology
·
2
A gut microbiota rheostat to forecast response to PDL1-VEGF blockade in mesothelioma.
2023
·
Dean Anthony Fennell
, Aleksandra Bzura
, et al.
·
Journal of Clinical Oncology
·
1
Atezolizumab and bevacizumab in patients with relapsed mesothelioma: MIST4—a phase IIa trial with cellular and molecular correlates of efficacy.
2022
·
Dean Anthony Fennell
, Amy King
, et al.
·
Journal of Clinical Oncology
·
1
Screening for carcinoid heart disease (CaHD): an audit of practice and assessment of deprivation index in sheffield NET centre, a european neuroendocrine centre of excellence
2024
·
Elsadig Abdelhaleem
, Osama Abdella
, et al.
·
Endocrine Abstracts
28P Epithelial mesenchymal transition confers resistance to dual PDL1-VEGF inhibition in relapsed mesothelioma
2022
·
E.Y. Baitei
, M. Zhang
, et al.
·
Immuno-Oncology Technology
Abstract 6086: Clonal biallelic inactivation of NF2 is an evolutionary bottleneck that exposes a vulnerability to CDK7 inhibition in mesothelioma
2022
·
Essa Y. Baitei
, Min Zhang
, et al.
·
Cancer Research
Show more works
View as search
Works count:
14
Citation count:
320
H-index:
6
I10-index:
6
Year
Topic
Type